# A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

> **NCT01463098** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 122 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** E2006 1.0 mg
- **DRUG:** E2006 2.5 mg
- **DRUG:** E2006 5.0 mg
- **DRUG:** E2006 10.0 mg
- **DRUG:** E2006 25.0 mg
- **DRUG:** E2006 50.0 mg
- **DRUG:** E2006 100 mg
- **DRUG:** E2006 200 mg
- **DRUG:** Zolpidem 10 mg
- **DRUG:** E2006 Matched Placebo or Zolpidem Matched Placebo
- **DRUG:** E2006 Matched Placebo

## Key facts

- **NCT ID:** NCT01463098
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-05
- **Primary completion:** 2012-08-11
- **Final completion:** 2012-08-11
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463098, "A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01463098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*